It has been shown that mutations in genes important for either the DNA damage response and the biological clock function an increased susceptibility to an increased susceptibility to cancer erectile dysfunction .
About CoGenesys, CoGenesys by out of Human Genome Sciences . The Company's strategy is to provide the security and effectiveness of the approach to finance in clinical trials by licensing or partnership of compounds for further development, demonstrate followed. CoGenesys has approximately 70 employees, including 20 Ph.D.-level scientists, and a dedicated 48,000 sq ft facility with cGMP manufacturing capacity sufficient for the early stages of clinical trials. 2.1 Inspection CoGenesys leading to the depth of the pipeline and the breadth of its technology drug candidates capitalize addressing of diseases and of diseases and applications, including cardiovascular disease, diabetes / metabolism, enzyme and protein replacement therapy and others. CoGenesys ' state-of - the-art research and production is fully equipped and supported by both preclinical development and cGMP manufacture of biologics. The clinically validated albumin fusion technology offers a number of advantages, including the ability to increase the bioavailability of existing biologicals, such as interferon alpha and Novartis developed) to improve, and increased feasibility of developing pharmaceutically relevant peptide such as GLP-1.
About GreystoneGreystone Associates is a medical and sanitary technology consulting firm offering services in the strategic planning, venture development of, products marketing well as technology and market assessments.